Clinical trials: Metastatic Colorectal Carcinoma
Solid Tumor
SMP-3124LP in Adults With Advanced Solid Tumors
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
- Trial name
- NCT06526819
- Testing
- SMP3124LP
- Where
- 13 sites in United States, Japan
- Volunteers
- 120 people
- Sponsor
- Sumitomo Pharma America, Inc.
Colorectal Cancer
PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study
The purpose of this study is to assess whether treatment with the study drug, panitumumab given concomitantly with every 2 (Q2) week oxaliplatin-based chemotherapy and bevacizumab improves progression-free survival (PFS) compared…
- Trial name
- NCT00115765
- Testing
- Oxaliplatin Based Chemotherapy, Panitumumab, Irinotecan Based Chemotherapy
- Volunteers
- 1,053 people
- Sponsor
- Amgen
Colorectal Cancer
SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic or locally recurrent colorectal cancer. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor.
- Trial name
- NCT00006001
- Testing
- semaxanib
- Where
- 10 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer
To document the antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer.
- Trial name
- NCT00459901
- Testing
- Erlotinib and capecitabine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Peter Kozuch
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT00004065
- Testing
- tanespimycin
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer
DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma
RATIONALE: Drugs used in chemotherapy, such as DJ-927, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00080834
- Testing
- DJ-927
- Where
- 2 sites in United States
- Sponsor
- Daiichi Sankyo
ColoRectal Cancer, Liver Metastasis Colon Cancer
COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal Ablation
The primary objective is to prove non-inferiority of thermal ablation compared to hepatic resection in patients with at least one resectable and ablatable colorectal liver metastases (≤3cm) and no extrahepatic disease.
- Conditions
- ColoRectal Cancer, Liver Metastasis Colon Cancer, Liver Metastases, Surgery
- Trial name
- COLLISION (NCT03088150)
- Testing
- Thermal ablation, Surgical resection
- Where
- Netherlands
- Volunteers
- 618 people
- Sponsor
- Amsterdam UMC, location VUmc
Gastrointestinal Tumor
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic gastrointestinal tumor and other solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum…
- Trial name
- NCT05262491
- Testing
- BL-B01D1
- Where
- 6 sites in China
- Volunteers
- 96 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Recurrent Colorectal Cancer
A Study of Radiotherapy Combined With Raltitrexed and Irinotecan in Metastatic or Locally Recurrent Colorectal Cancer
The study evaluates the effectiveness of radiotherapy combined with raltitrexed and irinotecan in treating patients who have metastatic or locally recurrent colorectal cancer that has not responded to fluorouracil.
- Trial name
- NCT04499586
- Testing
- Radiotherapy Combined With Raltitrexed and Irinotecan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00030797
- Testing
- Irinotecan 70 mg/m2, Irinotecan 240 mg/m2
- Where
- Switzerland
- Volunteers
- 75 people
- Sponsor
- Swiss Cancer Institute
Colorectal Cancer, Colorectal Neoplasms
Feasibility Study of a 4 Stage Bowel Obstruction Cancer Diet
Bowel obstruction is a common complication in patients with ovarian, peritoneal and bowel cancer due to a mass or spread of disease, causing narrowing to the gut, as these cancers can grow on the bowel surface.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Adenocarcinoma
- Trial name
- BOUNCED (NCT04898842)
- Testing
- Dietary intervention
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
This is a first-in-human (FIH), Phase 1 open-label, multicenter dose escalation study investigating AVA6103 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumors that…
- Conditions
- Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma
- Trial name
- FOCUS-01 (NCT07454642)
- Testing
- AVA6103
- Where
- 7 sites in United States
- Volunteers
- 174 people
- Sponsor
- Avacta Life Sciences Ltd
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic
Metastatic Colorectal Cancer
A Study of Trifluridine/ Tipiracil in Chemorefractory mCRC in Greece
Collection of real world data on the clinical efficacy of trifluridine/ tipiracil (FTD/TPI) in the Greek population.
- Trial name
- RETRO-TAS (NCT04965870)
- Testing
- Trifluridine/Tipiracil
- Where
- 8 sites in Greece
- Volunteers
- 200 people
- Sponsor
- Hellenic Study Group of Psychoneuroimmunology in Cancer
Colo-rectal Cancer, Third-line and Beyond Therapy
Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
This is a phase II, single-center, prospective trial aimed to investigate the efficacy and safety of a modified regimen of trifluridine/tipiracil plus bevacizumab in refractory metastatic colorectal cancer.
- Conditions
- Colo-rectal Cancer, Third-line and Beyond Therapy, TAS 102, Bevacizumab
- Trial name
- NCT07085169
- Testing
- Trifluridine/tipiracil (TAS-102) plus bevacizumab
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Colorectal Cancer
Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.
This study is designed to evaluate the safety, tolerability, and efficacy of Epalolitovoreli Monoclonal Antibody (QL1706) combined with Fruquintinib and Short-Course Radiotherapy (SCRT), compared with standard third-line therapy…
- Trial name
- NCT07353268
- Testing
- QL1706 + Fruquintinib + Short-Course Ablative Radiotherapy (SCART), Standard Third-Line Therapy
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Tao Zhang
Ovarian Cancer, Epithelial, Gastric Cancer
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
- Conditions
- Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05107674
- Testing
- NX-1607, Paclitaxel
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 345 people
- Sponsor
- Nurix Therapeutics, Inc.
Colorectal Cancer
Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)
The primary purpose of this study is to compare the efficacy of AZD2171 in combination with FOLFOX to the efficacy of bevacizumab in combination with FOLFOX, in the second-line treatment of patients with metastatic colorectal…
- Trial name
- HORIZON I (NCT00278889)
- Testing
- AZD2171, 5-fluorouracil, Leucovorin
- Where
- 43 sites in Austria, Belgium and 7 more
- Volunteers
- 215 people
- Sponsor
- AstraZeneca
Metastatic Colorectal Cancer, Chemotherapy Effect
Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer
This is a single-arm, open-label, single-center prospective phase II study to evaluate the efficacy and safety of rechallenge chemotherapy in the third or later-line treatment in patients with advanced colorectal cancer.
- Trial name
- NCT03485027
- Testing
- the rechallenge regimen
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Fudan University
Metastatic Colorectal Cancer
IXO+A in mCRC With Liver-only Metastases
The percentage of patients with defined unresectable metastatic disease who will benefit from a first-line treatment enabling secondary complete metastasectomy is unknown but limited.
- Trial name
- NCT01293942
- Testing
- irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab
- Where
- 4 sites in Canada
- Sponsor
- Ottawa Hospital Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.